Bruna Lucheze Freire

Bruna Lucheze Freire

Auto-generated profile, based on publicly available information

Bruna Lucheze Freire

Universidade Potiguar

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
BFBruna L Freire
Bruna L Freire
THThais K Homma
Thais K Homma
MFMariana F A Funari
Mariana F A Funari
ALAntônio M Lerario
Antônio M Lerario
GVGabriela A Vasques
Gabriela A Vasques
AJAlexander Augusto Lima Jorge
Alexander Augusto Lima Jorge
Context Patients born small for gestational age (SGA) who present with persistent short stature may have an underlying genetic etiology which accounts for prenatal and postnatal growth impairment. We have applied a unique massive parallel sequencing approach in cohort of exclusively nonsyndromic SGA patients to simultaneously interrogate for clinically significant genetic variants. Objective To perform a genetic investigation of children with isolated short stature born SGA. Design Screening by exome (n=16) or targeted gene panel (n=39) sequencing. Setting Tertiary referral center for growth disorders. Patients and Methods We selected 55 patients born SGA with persistent short stature without an identified cause of short stature. Main outcome measures Frequency of pathogenic findings. Results We identified heterozygous pathogenic or likely pathogenic genetic variants in eight of 55 patients, all of them in genes already associated with growth disorders. Four of the genes are associated with growth plate development, IHH (n=2), NPR2 (n=2), SHOX (n=1), and ACAN (n=1), and two of the genes are involved in the RAS/MAPK pathway, PTPN11 (n=1) and NF1 (n=1). None of these patients had clinical findings that allowed a clinical diagnosis. Seven patients were SGA only for length, and one patient was SGA for both length and weight. Conclusion These genomic approaches identified pathogenic or likely pathogenic genetic variants in eight of 55 patients (15%). Six of the eight patients carried variants in genes associated with growth plate development, indicating that mild forms of skeletal dysplasia may be a cause of growth disorders in this group of patients.

1 December 2019 in The Journal of Pediatrics
Verified
Journal Article
Closed access
THThais Kataoka Homma
Thais Kataoka Homma
BFBruna Lucheze Freire
Bruna Lucheze Freire
RKRachel Sayuri Honjo Kawahira
Rachel Sayuri Honjo Kawahira
ADAndrew Dauber
Andrew Dauber
MFMariana Ferreira de Assis Funari
Mariana Ferreira de Assis Funari
AJAlexander Augusto Lima Jorge
Alexander Augusto Lima Jorge

1 March 2018 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
BFBruna L. Freire
Bruna L. Freire
THThais K. Homma
Thais K. Homma
MFMariana F.A. Funari
Mariana F.A. Funari
ALAntonio Marcondes Lerario
Antonio Marcondes Lerario
ALAline M. Leal
Aline M. Leal
AJAlexander Augusto Lima Jorge
Alexander Augusto Lima Jorge

9 November 2017 in Hormone Research in Paediatrics
Verified
Journal Article
Open access
PDF file
THThais K. Homma
Thais K. Homma
AKAna Krepischi
Ana Krepischi
TFTatiane K. Furuya
Tatiane K. Furuya
RHRachel S. Honjo
Rachel S. Honjo
AMAlexsandra C. Malaquias
Alexsandra C. Malaquias
AJAlexander Augusto Lima Jorge
Alexander Augusto Lima Jorge
Background/Aims: Genetic imbalances are responsible for many cases of short stature of unknown etiology. This study aims to identify recurrent pathogenic copy number variants (CNVs) in patients with syndromic short stature of unknown cause. Methods: We selected 229 children with short stature and dysmorphic features, developmental delay, and/or intellectual disability, but without a recognized syndrome. All patients were evaluated by chromosomal microarray (array-based comparative genomic hybridization/single nucleotide polymorphism array). Additionally, we searched databases and previous studies to recover recurrent pathogenic CNVs associated with short stature. Results: We identified 32 pathogenic/probably pathogenic CNVs in 229 patients. By reviewing the literature, we selected 4 previous studies which evaluated CNVs in cohorts of patients with short stature. Taken together, there were 671 patients with short stature of unknown cause evaluated by chromosomal microarray. Pathogenic/probably pathogenic CNVs were identified in 87 patients (13%). Seven recurrent CNVs, 22q11.21, 15q26, 1p36.33, Xp22.33, 17p13.3, 1q21.1, 2q24.2, were observed. They are responsible for about 40% of all pathogenic/probably pathogenic genomic imbalances found in short stature patients of unknown cause. Conclusion: CNVs seem to play a significant role in patients with short stature. Chromosomal microarray should be used as a diagnostic tool for evaluation of growth disorders, especially for syndromic short stature of unknown cause.

2 June 2016 in Hormone Research in Paediatrics
Verified
Journal Article
Open access
PDF file
CBChristiaan de Bruin
Christiaan de Bruin
CFCourtney Finlayson
Courtney Finlayson
MFMariana F.A. Funari
Mariana F.A. Funari
GVGabriela A. Vasques
Gabriela A. Vasques
BFBruna Lucheze Freire
Bruna Lucheze Freire
AJAlexander Augusto Lima Jorge
Alexander Augusto Lima Jorge
Background: Acromicric dysplasia (AD) and geleophysic dysplasia 2 (GD2) belong to the category of acromelic dysplasia syndromes, consisting of severe short stature, short hands and feet and skin thickening. Both can result from missense mutations in the transforming growth factor beta 5 domain of the fibrillin-1 gene (FBN1). Methods: Two patients (P1 age 10, and P2 age 7) from unrelated families presented to their endocrinologist with severe short stature (approx. -4 SDS). They were otherwise asymptomatic and only had mild facial dysmorphisms. Extensive endocrine work-up did not reveal an underlying etiology. Exome sequencing was performed in each family. Results: Exome sequencing identified the presence of the same heterozygous missense variant c.C5183T (p.Ala1728Val) in the FBN1 gene in both P1 and P2. This variant was previously reported in a patient with GD2 and associated cardiac valvulopathy and hepatomegaly. Detailed clinical re-examination, cardiac and skeletal imaging did not reveal any abnormalities in P1 or P2 other than mild hip dysplasia. Conclusion: This report broadens the phenotypic spectrum of growth disorders associated with FBN1 mutations. Identical mutations give rise to a wide phenotypic spectrum, ranging from isolated short stature to a more classic picture of GD2 with cardiac involvement, distinct facial dysmorphisms and various skeletal anomalies.

12 November 2019 in Hormone Research in Paediatrics
Verified
Journal Article
Closed access
PDF file
THThais K. Homma
Thais K. Homma
BFBruna L. Freire
Bruna L. Freire
RHRachel Honjo
Rachel Honjo
ADAndrew Dauber
Andrew Dauber
MFMariana F.A. Funari
Mariana F.A. Funari
AJAlexander Augusto Lima Jorge
Alexander Augusto Lima Jorge
Background: Floating-Harbor syndrome (FHS) is a rare condition characterized by dysmorphic facial features, short stature, and expressive language delay. Objective: The aim of this study was to describe a cohort of patients with FHS and review the literature about the response to recombinant human growth hormone (rhGH) therapy. Methods: Anthropometric and laboratory data from 7 patients with FHS were described. The molecular diagnosis was established by multigene analysis. Moreover, we reviewed the literature concerning patients with FHS treated with rhGH. Results: All 7 patients were born small for gestational age. At first evaluation, 6 patients had a height standard deviation score (SDS) ≤–2 and 1 had short stature in relation to their target height. Bone age was usually delayed, which rapidly advanced during puberty. Nonspecific skeletal abnormalities were frequently noticed, and normal to elevated plasma IGF-I levels were observed in all except 1 patient with growth hormone deficiency. Information about 20 patients with FHS treated with rhGH was analyzed (4 from our cohort and 16 from the literature). The median height changes during the treatment period (approx. 2.9 years) were 1.1 SDS (range from –0.4 to 3.1). Nontreated patients had an adult height SDS of –4.1 ± 1.2 (n = 10) versus –2.6 ± 0.8 SDS (n = 7, p 0.012) for treated patients. Conclusion: We observed a laboratory profile compatible with IGF-1 insensitivity in some patients with FHS. Nevertheless, our study suggests that children with FHS may be considered as candidates for rhGH therapy. Further studies are necessary to establish the real benefit and safety of rhGH therapy in these patients.